Healthcare / BiotechnologyParis
$2.80
-0.03 (-1.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-3.7M · quality 73.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$100M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-123.0%
↓Gross Margin
13.1%
↓Debt/Equity
0.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.2%
FCF CAGR
—
FCF margin
-78.1%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.1M · net income $-5.5M · FCF $-3.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.1M | $4.1M | $4.6M | $4.6M | $5.3M |
| Net Income | $-5.5M | $-5.5M | $-4.4M | $-3.5M | $-4.2M |
| EBITDA | $-5.3M | $-5.3M | $-4.2M | $-3.3M | $-4.0M |
| EPS | -0.16 | -0.16 | -0.13 | -0.11 | -0.15 |
| Gross Margin | 13.1% | 13.1% | 18.5% | 13.3% | 12.1% |
| Operating Margin | -133.6% | -133.6% | -95.0% | -68.2% | -75.7% |
| Net Margin | -136.6% | -136.6% | -96.3% | -75.8% | -80.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.84 | 0.84 | 0.37 | 0.43 | 0.56 |
| Current Ratio | 1.06 | 1.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.2M | $-3.2M | $-3.7M | $-3.8M | $-3.5M |
| Returns | |||||
| ROE | -123.0% | -123.0% | -58.3% | -44.4% | -58.7% |
| Valuation | |||||
| P/B | 23.77 | 23.77 | 5.58 | 5.14 | 7.66 |
| Growth & Yield | |||||
| Revenue Growth | -10.7% | -10.7% | -1.9% | -11.7% | — |
| EPS Growth | -25.9% | -25.9% | -16.9% | 27.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+119.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.13 → -0.16
Residual
+119.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.